Myeloma
Myeloma, commonly referred to as multiple myeloma, is a blood cancer that develops from plasma cells. It can be benign or malignant. In the UK, there are approximately 17,500 myeloma patients at any given moment. It is responsible for 2% of all malignancies and 15% of blood cancers. Myeloma primarily affects those over 65, but it has been identified in those as young as 20.
- Multiple Myeloma
- Signal Transduction
- Metastatic Cancer
- Hematologic Cancer
- Signaling Pathway
- Information on Drugs
- Medicine for Inflammation
Related Conference of Myeloma
Myeloma Conference Speakers
Recommended Sessions
- Anemia
- Biomarkers in Hematology
- Bleeding Disorders
- Clinical and Experimental Hematology
- Coagulopathies
- Gene and Cell Therapies for Blood Disorders
- Hematologic Malignancies
- Hematology and neurological disorders
- Hematology in COVID-19 patients
- Hematology in Pediatrics
- Hematology-oncology
- Hematopoietic Stem Cell Transplantation
- Hemostasis
- HIV/AIDS
- Immunohematology
- Immunotherapy for Blood Disorders
- Leukemia
- Myeloma
- Rare Blood Disorders
- Thalassemia
- Thrombosis and Hemostasis
Related Journals
Are you interested in
- Advances in Hematologic Malignancies - Blood Disorders 2025 (Italy)
- Advances in Hemostasis and Thrombosis - Blood Disorders 2025 (Italy)
- Blood Disorders and the Immune System - Blood Disorders 2025 (Italy)
- Blood Disorders Diagnosis & Treatment - HEMATOLOGY 2025 (Spain)
- Blood Disorders in Aging Populations - Blood Disorders 2025 (Italy)
- Blood Transfusion - HEMATOLOGY 2025 (Spain)
- Case reports of Hematology - HEMATOLOGY 2025 (Spain)
- CellTherapy - HEMATOLOGY 2025 (Spain)
- COVID-19 and Hematology - HEMATOLOGY 2025 (Spain)
- Cutting-Edge Research in Blood Disorders - Blood Disorders 2025 (Italy)
- Disorders of Vascular Bleeding - HEMATOLOGY 2025 (Spain)
- Future Trends in Hematology: Artificial Intelligence and Big Data - Blood Disorders 2025 (Italy)
- Gene Therapy and Genetic Engineering in Hematology - Blood Disorders 2025 (Italy)
- Hematologic Toxicities and Side Effects of Cancer Therapy - Blood Disorders 2025 (Italy)
- Hematology - HEMATOLOGY 2025 (Spain)
- Hematology in Global Health: Addressing Disparities - Blood Disorders 2025 (Italy)
- Hematology Oncology - HEMATOLOGY 2025 (Spain)
- Immunohematology - HEMATOLOGY 2025 (Spain)
- Immunotherapy and Cellular Therapies in Hematology - Blood Disorders 2025 (Italy)
- Innovations in Red Blood Cell Disorders - Blood Disorders 2025 (Italy)
- Leukaemia and Lymphoma - HEMATOLOGY 2025 (Spain)
- Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation - HEMATOLOGY 2025 (Spain)
- New Drug Development in Hematology - HEMATOLOGY 2025 (Spain)
- Novel Diagnostic Techniques and Biomarkers in Hematology - Blood Disorders 2025 (Italy)
- Patient Blood Management - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology: Challenges and Innovations - Blood Disorders 2025 (Italy)
- Stem Cell Research - HEMATOLOGY 2025 (Spain)
- Stem Cell Transplantation and Regenerative Medicine - Blood Disorders 2025 (Italy)
- Thalassemia - HEMATOLOGY 2025 (Spain)
- Therapeutic Apheresis - HEMATOLOGY 2025 (Spain)
- Thrombosis and Coagulation - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine: Advances and Challenge - Blood Disorders 2025 (Italy)
- Transfusion Transmissible Infections - HEMATOLOGY 2025 (Spain)